Last reviewed · How we verify
T3 (Triiodothyronine)
T3 (triiodothyronine) is a thyroid hormone that binds to thyroid hormone receptors in cells to increase metabolic rate and cellular energy production.
T3 (triiodothyronine) is a thyroid hormone that binds to thyroid hormone receptors in cells to increase metabolic rate and cellular energy production. Used for Adjunctive treatment for major depressive disorder (investigational), Hypothyroidism (established therapeutic use).
At a glance
| Generic name | T3 (Triiodothyronine) |
|---|---|
| Sponsor | National Institute of Mental Health (NIMH) |
| Drug class | Thyroid hormone |
| Target | Thyroid hormone receptor (TR-alpha, TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
T3 is the active form of thyroid hormone that enters cells and binds to thyroid hormone receptors (TR-alpha and TR-beta), which act as nuclear transcription factors. This binding increases the expression of genes involved in oxidative metabolism, thermogenesis, and cellular respiration. T3 has been studied as an adjunctive treatment in mood disorders, particularly depression, based on evidence that thyroid dysfunction is associated with psychiatric symptoms.
Approved indications
- Adjunctive treatment for major depressive disorder (investigational)
- Hypothyroidism (established therapeutic use)
Common side effects
- Tachycardia
- Tremor
- Anxiety
- Insomnia
- Heat intolerance
- Weight loss
Key clinical trials
- Comparison Of The Effects Of Regional Anesthesia On Brain And Carotid Artery Oxygenation In Shoulder Surgery (NA)
- Internet-based Mindfulness-based Training (iMBT) for People With Depression (NA)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
- Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer (NA)
- Paravertebral Block for Mastectomy With Immediate Reconstruction (NA)
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T3 (Triiodothyronine) CI brief — competitive landscape report
- T3 (Triiodothyronine) updates RSS · CI watch RSS
- National Institute of Mental Health (NIMH) portfolio CI